Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnesium sulfate + sodium bicarbonate + dextrose is an investigational combination injectable formulation developed by Queen's University for the treatment of chronic myofascial pelvic pain in women. The formulation is administered via trigger point infiltration. Magnesium sulfate acts as a calcium antagonist to inhibit the pathologic myocyte contractions that propagate myofascial pain. Dextrose is included for its prolotherapy properties, intended to stimulate a regenerative tissue response in painful syndromes. Sodium bicarbonate serves as a buffering agent to neutralize the pH of the solution and reduce injection-site discomfort. The drug was evaluated in a randomized, double-blind, controlled trial (NCT02728037) comparing it to lidocaine-only injections for the relief of chronic pelvic pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium sulfate + sodium bicarbonate + dextrose.